Fluidx Medical disclosed study results examining extent of vessel filling using the GPX embolic device compared to microspheres, a common treatment for many types of tumours.
“GPX is demonstrating deep distal vessel penetration,” said Ryan O’Hara, interventional oncologist at the University of Utah (Salt Lake City, USA). “The ability to fill the smallest tumour-feeding vessels and reach distal vessel beds is very important in effective treatment of hypervascular tumours and in other therapeutic embolic procedures.”
Embolizing blood supply to tumours is a high-growth procedure to block blood supply to certain tumours. Transarterial chemoembolization (TACE) includes delivering chemotherapy with embolization. Tumour embolization may also be performed prior to resection.
“GPX exhibited effective and thorough embolization throughout the renal cortical vasculature,” according to a pathology assessment conducted by study pathologist James Stanley. “GPX filled the smallest arteries/arterioles of the distal cortex which was not observed with 40-micron microspheres.”
GPX and microspheres were studied in selected small branches of renal arteries. The GPX embolic device was found to fill vessels more completely and penetrate deeper into smaller vessel beds than the smallest microspheres commonly used for tumour treatments.
“The extent of distal penetration of GPX, combined with its potential as a drug-loadable oncology solution, make this a unique technology with an exciting future in advancing cancer care,” said Danny Smith, Fluidx Medical vice president of research and development.